Posted by Michael Wonder on 24 May 2022
NICE doesn’t recommend ibrutinib for those with Waldenstrom’s macroglobulinaemia
23 May 2022 - Ibrutinib, a drug used to treat Waldenström’s macroglobulinaemia, is not being recommended by NICE in England for adults who have had at least one previous treatment.
The drug, which is sold under the brand name Imbruvica, has been available for people in England through the Cancer Drugs Fund since November 2017.
